LA Private

October 2024

Commercial hydrogen production in sight as Hazer achieves key milestone

Hazer Group Limited (ASX:HZR) continues to make significant progress with its clean hydrogen production technology, as highlighted in its latest quarterly report for the period ending 30 September 2024. The company achieved a major milestone with over 360 hours of continuous operation of its Commercial Demonstration Plant (CDP), showcasing high reliability and methane conversion efficiency. […]

Commercial hydrogen production in sight as Hazer achieves key milestone Read More »

PYC Therapeutics earns FDA orphan drug designation for RP11 therapy

PYC Therapeutics (ASX:PYC) has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its drug candidate VP-001, aimed at treating Retinitis Pigmentosa type 11 (RP11). This breakthrough therapy is currently undergoing multiple clinical trials, representing a significant step forward for patients affected by this childhood disease. The ODD status confers

PYC Therapeutics earns FDA orphan drug designation for RP11 therapy Read More »

Acusensus to trial cutting-edge road safety technology in Queensland

Acusensus Limited (ASX:ACE) is set to trial its Behaviour Awareness Monitoring (BAM) system on Queensland roads by the end of 2024. This innovative system, designed to reduce dangerous driving behaviour, alerts drivers in real-time if they are using mobile phones or tailgating. The BAM system also rewards safe driving practices, enhancing community education around road

Acusensus to trial cutting-edge road safety technology in Queensland Read More »

Race Oncology concludes successful Phase 1b/2 trial, secures R&D tax incentive

Race Oncology (ASX:RAC) has completed its Phase 1b/2 trial of bisantrene in combination with clofarabine and fludarabine for the treatment of relapsed or refractory acute myeloid leukaemia (AML). AML is a type of cancer that starts in the bone marrow and often moves into the blood. It is characterised by the rapid growth of abnormal

Race Oncology concludes successful Phase 1b/2 trial, secures R&D tax incentive Read More »

Down, down for global inflation & rates, Soft Chinese data, Jobs & RBA, US earnings, Baby bonus?

Dr Shane Oliver, Head of Investment Strategy & Chief Economist at AMP, discusses developments in investment markets over the past week, economic activity trackers, major global economic events and Australian economic events. Investment markets and key developments over the past week Global share markets were mixed over the last week with US shares up as

Down, down for global inflation & rates, Soft Chinese data, Jobs & RBA, US earnings, Baby bonus? Read More »

Go, Harvey, Go… to court

The Federal Court of Australia has ruled in favour of the Australian Securities and Investments Commission (ASIC), finding that Harvey Norman (ASX:HVN) and Latitude Finance Australia engaged in misleading and deceptive advertising practices. The case stemmed from promotional campaigns that ran from January 2020 to August 2021, which offered interest-free payment plans for Harvey Norman

Go, Harvey, Go… to court Read More »